Latest Safety News

Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.

EROAD Limited reported solid financial results for FY25, with revenue up 6.8% to NZ$194.4 million and a substantial improvement in free cash flow to NZ$16 million. The company’s strategic focus on enterprise fleet growth and innovation underpins a confident FY26 guidance.

GreenHy2 Limited has broadened its renewable energy storage portfolio by integrating graphene-based hybrid supercapacitor batteries, reporting robust FY24 growth and advancing key customer trials.

Catalyst Metals Limited has secured A$150 million in equity to fund organic growth and exploration across its flagship Plutonic Gold Belt and Bendigo Gold Belt projects. The company aims to nearly double gold production to around 200,000 ounces per annum while reducing costs through strategic acquisitions and infrastructure leverage.

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

Australis Oil & Gas reported a robust 2024 performance with strong safety and environmental records, maintaining strategic focus on its Tuscaloosa Marine Shale asset despite challenging market conditions.

SKS Technologies has delivered a robust first half in 2025, showcasing strong revenue growth and a burgeoning project pipeline, underpinned by zero debt and strategic expansion in data centres and traditional electrical services.

HyTerra Limited has reported exceptional hydrogen and helium concentrations from its Sue Duroche 3 well in Kansas, marking a significant milestone in natural gas exploration and clean energy potential.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in treating FSGS kidney disease has passed its sixth independent safety review with no concerns, reinforcing the drug’s promising safety profile.

Hawsons Iron Ltd confirms the technical viability of a fully dry processing circuit for its Hawsons Iron Project, promising cost and environmental benefits. An updated prefeasibility study and maiden ore reserves are expected soon.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Lincoln Minerals’ Kookaburra Graphite Project has delivered battery-grade graphite purity exceeding 99.95%, confirming its suitability for lithium-ion battery anodes through a safer, hydrofluoric acid-free process.